Tech Company Financing Transactions
Deciphex Funding Round
On 1/7/2025, Deciphex raised $32 million in Series C financing from Molten Ventures, ACT Venture Capital and Charles River Laboratories.
Transaction Overview
Company Name
Announced On
1/7/2025
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series C
Investors
Molten Ventures (Lead Investor)
ACT Venture Capital (John O'Sullivan)
Proceeds Purpose
The company intends to use the funds to: scale global service reach. enhance utility of its platforms. accelerate pathology AI foundational model development. strengthen partnerships with industry leaders. expand services to Pharma/Biotech and CRO clients.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
1012 95th St. Naperville
Chicago, IL 60564
USA
Chicago, IL 60564
USA
Phone
Website
Email Address
Overview
Patholytix is the industry-leading digital pathology workflow & integrated AI platform for Research Pathology. Patholytix is trusted by the leading CROs and pharmaceutical companies for handling high volume drug safety pathology studies, providing a complete GLP-compliant workflow with integrated AI screening capabilities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Donal O'Shea
Chief Medical Officer
Runjan Chetty
Chief Operating Officer
Mairin Rafferty
Vice President
Luke Benko
VP - Bus. Development
John Nolan
VP - Sales
Colin Doolan
Browse more venture capital transactions:
Prev: 1/7/2025: Weimai venture capital transaction
Next: 1/7/2025: ThreatMark venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs